Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_assertion type Assertion NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_head.
- NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_assertion description "[Female Sprague-Dawley rats were either treated with N(G)-nitro-L-arginine methyl ester (L-NAME; 0.5 g/l in drinking water) for 5 wk (HTN; n = 8), L-NAME for 5 wk plus the PPAR-gamma agonist rosiglitazone (20 mg/kg in food) for the last 3 wk (HTN + Rosi; n = 5), L-NAME for 5 wk plus the superoxide dismutase mimetic Tempol (1 mmol/l in drinking water) for the last 3 wk (HTN + Tempol; n = 8), or were untreated controls (n = 9).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_provenance.
- NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_assertion evidence source_evidence_curated NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_provenance.
- NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_assertion SIO_000772 19666838 NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_provenance.
- NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_assertion wasDerivedFrom ctd_human-20130708 NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_provenance.
- NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_assertion wasGeneratedBy ECO_0000218 NP26928.RAz8vFaSg4PCscMYHmv0Lz4wm6HbpQthn73s0gg1nK3zU130_provenance.